<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mahaffey, Kenneth W.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results from the TRA•CER Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">The results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome [TRA•CER] trial showed that vorapaxar does not significantly improve outcomes in high-risk patients with non-ST-segment elevation acute coronary syndrome and significantly increases the risk of major bleeding, including intracranial hemorrhage.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>